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CytotoxicityCytidine (cyt) and adenosine (ado) react with cis-[L2Pt(μ-OH)]2(NO3)2 (L=PMe3, PPh3) in various solvents to
give the nucleoside complexes cis-[L2Pt{cyt(−H),N3N4}]3(NO3)3 (L=PMe3, 1), cis-[L2Pt{cyt(−H),N4}(cyt,N3)]
NO3 (L=PPh3, 2), cis-[L2Pt{ado(−H),N1N6}]2(NO3)2 (L=PMe3, 3) and cis-[L2Pt{ado(−H),N6N7}]NO3
(L=PPh3, 4). When the condensation reaction is carried out in solution of nitriles (RCN, R=Me, Ph) the
amidine derivatives cis-[(PPh3)2PtNH=C(R){cyt(−2H)}]NO3 (R=Me, 5a; R=Ph, 5b) and cis-[(PPh3)2PtNH=
C(R){ado(−2H)}]NO3 (R=Me, 6a: R=Ph, 6b) are quantitatively formed. The coordination mode of these
nucleosides, characterized in solution bymultinuclear NMR spectroscopy andmass spectrometry, is similar to
that previously observed for the nucleobases 1-methylcytosine (1-MeCy) and 9-methyladenine (9-MeAd).
The cytotoxic properties of the new complexes, and those of the nucleobase analogs, cis-[(PPh3)2PtNH=C(R)
{1-MeCy(−2H)}]NO3 (R=Me, 7a: R=Ph, 7b), cis-[(PPh3)2PtNH=C(R){9-MeAd(−2H)}]NO3 (R=Me, 8a:
R=Ph, 8b) have been investigated in a wide panel of human cancer cells. Interestingly, whereas the Pt(II)
nucleoside complexes (1–4) did not show appreciable cytotoxicity, the corresponding amidine derivatives (7a,
7b, 8a, 8b, 5b, and 6b) exhibited a significant in vitro antitumor activity.ertacco, a Ph. D. student of our
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.
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The coordination chemistry of DNA components tometal centers has
been thoroughly characterized [1–3]. In particular, after the discovery of
biological activity of cis-Pt(NH3)2Cl2 [4–6], the interactions of platinum
(II and IV)[7–10] complexes with model nucleobases, nucleosides and
nucleotides, have been studied in great detail [11–17]. In this field we
have shown that the neutral ligands in the cisplatin analogs cis-Pt
(PR3)2Cl2 (PR3=phosphines and diphosphines) play an important role
in thenuclearity and reactivity of theplatinum-nucleobase adducts. As an
example, the reaction of the hydroxo complex cis-[L2Pt(μ-OH)]2(NO3)2
with 1-methylcytosine (1-MeCy) causes the deprotonation of the
nucleobase leading to cis-[L2Pt{μ-1-MeCy(−H),N3,N4}]3(NO3)3 when L
is PMe3 [18] and to themononuclear complex cis-[L2Pt{1-MeCy(−H),N4}
(1-MeCy,N3)]NO3 with L=PPh3 [19]. In addition, the trinuclear species
is stable in solution of nitriles (MeCN, PhCN), whereas the mononu-
clear species reacts with the solvent to give the amidine derivatives
cis-[(PPh3)2PtNH=C(R){1-MeCy(−2H)}]NO3 (R=Me, Ph) [20,21].
We have now extended these studies on the reactivity of cis-[L2Pt
(μ-OH)]2(NO3)2 (L=PMe3, PPh3) to the nucleosides cytidine (cyt)
and adenosine (ado), shown in Scheme 1.In this paper we report the synthesis and characterization of new
nucleoside complexes along with an investigation on their cytotoxic
properties against a panel of human cancer cell lines. The high
antitumor activity exhibited by the species cis-[(PPh3)2PtNH=C(Ph)
{cyt(−2H)}]NO3 and cis-[(PPh3)2PtNH=C(Ph){ado(−2H)}]NO3,
quantitatively formed when the condensation reaction between the
nucleoside and cis-[(PPh3)2Pt(μ-OH)]2(NO3)2 is carried out in benzo-
nitrile, prompted us to include, in this biological investigation, some of
the related amidine nucleobase adducts, previously described.
2. Experimental section
2.1. General methods
Adenosine, cytidine and all the solvents (MeOH, Et2O, PhCN, CH3CN,
DMF(dimethylformamide), CDCl3,D2O;DMSO-d6,) areAldrichproducts.
cis-[(PPh3)2Pt(μ-OH)]2(NO3)2 [20], cis-[(PMe3)2Pt(μ-OH)]2(NO3)2 [22],
cis-[(PPh3)2PtHN=C(Me){1-MeCy(−2H)}]NO3 (7a) [20], cis-[(PPh3)2
PtHN=C(Ph){1-MeCy(−2H)}]NO3 (7b) [21], cis-[(PPh3)2PtHN=C(Me)
{9-MeAd(−2H)}]NO3 (8a) [20], cis-[(PPh3)2PtHN=C(Me){9-MeAd
(−2H)}]NO3 (8b) [21] were synthesized as previously reported.
2.2. NMR and ESI mass spectroscopy
1H and 31P NMR experiments were recorded on a Bruker AVANCE
300 MHz (operating at 300.13, and 121.49 MHZ respectively) and 15N
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Scheme 1. Representation of cytidine (cyt) and adenosine (ado).
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40.6 MHz). The 1H chemical shifts were referenced to the residual
impurity of the solvent and to TMS (tetramethylsilane). The external
references were H3PO4 (85% w/w in D2O) for 31P and CH3NO2 (in
CDCl3 at 50% w/w) for 15N. Inverse detected spectra were obtained
through heteronuclear multiple bond correlation (HMBC) experi-
ments, using parameters similar to those previously reported [23].
ESI-MS (electrospray ionization mass spectrometry) spectra were
performed with a MSD SL trap mass spectrometer (Agilent Technol-
ogies, Palo Alto, CA, USA) operating in positive ionmode fromm/z 100
to 2200. A 5×10−6 M solutionwas directly infused into the ion source
at a flow rate of 10 μL min−1 by a syringe pump.
2.3. Synthesis of the complexes
2.3.1. cis-[(PMe3)2Pt{cyd(−H),N3N4}]3(NO3)3 (1)
A mixture of cis-[(PMe3)2Pt(μ-OH)]2(NO3)2 (238 mg, 0.279 mmol)
and cytidine (136 mg, 0.56 mmol) was dissolved in 10 mL of DMF and
the solutionwas heated at 75 °C for 10 days. Addition of Et2O afforded a
yellow oil which, treated several times with Et2O, became a pale yellow
solid. The solid was washed again with Et2O and dried under vacuum
obtaining 321 mg (yield 88%). El. An. Calc. per C15H30N4O8P2Pt⋅DMF: C:
29.84;H: 5.16; N: 9.66. Found: C: 29.40;H: 4.85; N: 9.42. 31P{1H}NMR in
D2O: AB multiplet at δ (ppm)=−28.21 (1JPPt=3252 Hz) and−30.11
(1JPPt=3117 Hz) with 2JPP=24.5 Hz; AB multiplet at δ (ppm)=
−28.25 (1JPPt=3252 Hz) and −29.91 (1JPPt=3117 Hz) with 2JPP=
24.5 Hz. Relative intensities 60/40. 1H NMR in D2O (δ): 7.56 and 7.55 (d
(doublet), 1H, H6, 3JHH=7.68 Hz); 6.67 and 6.62 (s (singlet), 1H, NH);
6.29 (d, 1H, H5, 3JHH=7.68 Hz); 5.88 and 5.76 (d, 1H, H1′,
3JHH=5.11 Hz); 4.29 and 4.23 (1H, H2′); 4.11 (1H, H4′); 4.07 (1H,
H3′); 3.82 (2H, H5′); 1.78 (d, 3 H, PCH3, 2JPH=11.57 Hz); 1.61 (d, 3 H,
PCH3, 2JPH=10.99 Hz). 31P{1H} NMR in DMF (D2O insert): AB multiplet
at δ (ppm)=−27.01 (1JPPt=3126 Hz) and −28.31 (1JPPt=3234 Hz)
with 2JPP=24.9 Hz;ABmultiplet atδ (ppm)=−27.14 (1JPPt=3126 Hz)
and −28.58 (1JPPt=3234 Hz) with 2JPP=24.9 Hz. Relative intensities
65/35. 1H NMR in DMSO-d6 (δ): 7.49 (d, 1H, H6, 3JHH=8.2 Hz); 7.27 (s,
1H, NH); 5.97 (d, 1H, H5, 3JHH=8.2 Hz); 5.76 (d, 1H, H1′); 5.28 (d, 1H,
OH2′); 5.13 (d, 1H, OH3′); 5.04 (dd (doublet of doublet), 1H,OH5′); 3.91
(d, 1H,H2′); 3.89 (d, 1H,H3);3.49(d, 1H,H4′); 3.52 (d, 2H,H5′); 1.77 (d,
3 H, PCH3, 2JPH=11.5 Hz); 1.50 (d, 3 H, PCH3, 2JPH=11.8 Hz). ESI-MS
(m/z) in MeOH, main peak at 915.2 (calc. 914.7) corresponding to the
dication cis-[(PMe3)2Pt{cyd(−H)}]3(NO3)2+.
In order to analyze the cytotoxic properties of 1, the compound has
been obtained with an analogous procedure in water, heating the
sample at 40 °C for two weeks.2.3.2. cis-[(PPh3)2Pt{cyd(−H),N4}(cyd,N3)]NO3 (2)
cis-[(PPh3)2Pt(μ-OH)]2(NO3)2 (230.9 mg, 0.145 mmol) and cyti-
dine (70.5 mg, 0.26 mmol) were suspended in 4 mL of DMF. After
10 min, a pale yellow solution was obtained. After 24 h, addition of
30 mL of Et2O afforded a yellow oil which, following isolation and
repeated washes with Et2O, lead to the formation of a white solid,
that was dried under vacuum. The yield of 2 was 314 mg (86%). El.
An. Calc. for C54H55N7O13P2Pt⋅DMF: C: 51.08; H: 4.67; N: 8.36. Found
C: 51.92; H: 4.95; N: 8.82. (Although the analysis value for “C” is
somewhat unsatisfactory, the 1H and 31P NMR data reasonably support
the formula). 31P{1H} NMR in DMF (D2O insert): AB multiplet at δ
(ppm)=12.55 (1JPPt=3194 Hz) and 0.68 (1JPPt=3586 Hz) with
2JPP=20.3 Hz; AB multiplet at δ (ppm)=12.55 (1JPPt=3194 Hz) and
1.16 (1JPPt=3584 Hz) with 2JPP=20.3 Relative intensities 75/25 Hz. 1H
NMR in DMSO-d6 (δ): 7.65–7.21 (c.m.(complex multiplet), 31H, PPh3
and H6 of cyd(−H)); cyd resonances: 10.88 and 10.82 (s, 1H, NH); 8.58
and 8.55 (s, 1H, NH); 7.22 (d, 1H, H6, 3JHH=6.78 Hz); 5.30 (d, 1H, H5,
3JHH=5.67 Hz); cyd(−H) resonances: 7.49 (d, 1H, H6, 2JHH=7.67 Hz);
5.50 (1H, NH); 5.09 (d, 1H, H5, 3JHH=7.67 Hz); ribose resonances: 5.80
(2H, OH2′); 5.38 (2H, OH3′); 5.30 (2H, H1′); 5.08 (2H, OH4′); 5.00 (2H,
OH5′); 3.86 (6 H, H2′, H3′ and H4′); 3.58 (4 H, H5′).
2.3.3. cis-[(PMe3)2Pt{ado(−H),N1N6}]2(NO3)2 (3)
cis-[(PMe3)2Pt(μ-OH)]2(NO3)2 (229.1 mg, 0.269 mmol) and aden-
osine (143.5 mg, 0.537 mmol) were dissolved in 10 mL of H2O. After
4 days, the solution was dried under vacuum and the solid recrys-
tallized from MeOH and Et2O. Obtained 308 mg (yield 85%). El. An.
Calc. for C16H30N6O7P2Pt⋅H2O: C: 27.71, H: 4.66, N: 12.11. Found: C:
28.03, H: 4.83, N: 12.48. 31P{1H} NMR in D2O: AB multiplet at δ
(ppm)=−30.78 (1JPPt=3080 Hz) and−31.31 (1JPPt=3238 Hz)with
2JPP=25.9 Hz; 1H NMR in D2O (δ): 8.16 (s, 1H, H8); 8.14 (s, 1H, H2);
6.34 (s, 1H, N6H); 5.77 (1H, H1′); 4.24 (1H, H2′); 4.10 (1H, H3′); 4.50
(1H, H4′); 3.68 (2H, H5′); 1.89 (d, 3 H, PCH3, 2JPH=10.8 Hz); 1.43 (d,
3 H, PCH3, 2JPH=10.3 Hz). 1H NMR in DMSO-d6 (δ): 8.36 and 8.35 (s,
1H,H8); 8.16 and8.14 (s, 1H,H2); 6.81 and6.78 (s, 1H,N6H); 5.71 (1H,
OH2′); 5.41 e 5.38 (1H, H1′); 5.19 (1H, OH3′); 5.03 (1H, OH5′); 4.37
(1H, H2′); 4.06 (1H, H3′); 3.86 (1H, H4′); 3.54 (2H, H5′); 1.87 (d, 3 H,
PCH3, 2JPH=11.1 Hz); 1.44 (d, 3 H, PCH3, 2JPH=10.4 Hz).
2.3.4. cis-[(PPh3)2Pt{ado(−H),N6N7}]NO3 (4)
cis-[(PPh3)2Pt(μ-OH)]2(NO3)2 (230.5 mg, 0.144 mmol) and aden-
osine (77.1 mg, 0.286 mmol) were suspended in a mixture of CH2Cl2
and MeOH (3+3 mL). After 30 min of stirring, a pale yellow solution
was obtained. After 24 h the addition of 30 mL of Et2O afforded a
yellow oil which, after being isolated and washed several times with
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vacuum.Obtained 252 mg (yield 83%). El. An. Calc. for C46H42N6O7P2Pt.-
H2O: C: 51.83; H: 4.17; N: 7.88. FoundC: 51.47; H: 4.42;N: 7.98. 1HNMR
in DMSO-d6 (δ): 8.05 (s, 1H, H2); 7.74–7.10 (c.m. 30 H, PPh3); 6.76 (s,
1H, H8); 5.87 (d, 1H, OH2′, 3JHH=6.1 Hz); 5.38 (d, 1H, OH3′, 3JHH=
5.9 Hz); 5.20 (2H, H1′ e NH); 5.04 (1H, OH5′); 4.42 (1H, H2′); 4.30 (1H,
H3′); 4.14 (1H, H4′); 3.95 (1H, H5′); 3.88 (1H, H5″). 31P{1H} NMR in
CDCl3: AB multiplet at δ (ppm)=8.29 (1JPPt=3844 Hz) and 6.58
(1JPPt=3124 Hz) with 2JPP=20.2 Hz; 1H NMR in CDCl3 (δ): 8.12 (s, 1H,
H2); 7.55–7.27 (c.m. 30 H, PPh3); 6.39 (d, 1H, OH5′, 3JHH=9.88 Hz);
6.28 (d, 1H, OH2′, 3JHH=6.58 Hz); 5.83 (s, 1H, H8); 5.43 (d, 1H, H1′,
3JHH=6.97 Hz); 4.66 (2H,H2′ eNH); 4.36 (2H,H3′ andOH3′); 4.26 (1H,
H4′); 3.89÷3.66 (c.m. 2H, H5′). 15N NMR (inverse detected) in CDCl3
(δ): −191.4 (N7); −135.2 (N3); −160.9 (N1); −200.0 (N9); −242.1
(N6). ESI-MS (m/z) in MeOH, main peak at 985.4 (calc. 985.2)
corresponding to the monocation cis-[(PPh3)2Pt{ado(−H)}]+.
2.3.5. cis-[(PPh3)2PtHN=C(Me){cyt(−2H)}]NO3 (5a)
cis-[(PPh3)2Pt(μ-OH)]2(NO3)2, (45 mg, 0.028 mmol) and cyti-
dine (14 mg, 0.057 mmol) were suspended in 5 mL of CH3CN. After
stirring at r.t. for 24 h, some traces of solid were removed by filtra-
tion. Addition of Et2O to the resulting pale yellow solution, afforded
a pale yellow solid which was recovered by filtration, washed with
Et2O and dried under vacuum. The amount of 5a obtained was
46 mg (yield 76%). El. An. Calc. for C47H45N5O8P2Pt: C: 53.01; H:
4.27; N: 6.57. Found: C: 52.75; H: 4.18; N: 6.40. 31P{1H} NMR in
CH3CN (D2O insert): AB multiplet at δ (ppm)=9.11 (1JPPt=
3481 Hz) and 8.71 (1JPPt=3465 Hz) with 2JPP=21.1 Hz. 1H NMR
in CDCl3 (δ, ppm): 7.95 (d, 1H, H6, 3JHH=7.45 Hz); 7.65–7.14 (c.m.
30 H, PPh3); 6.00 (d, 1H, H5, 3JHH=7.45 Hz); 5.50 (br dd, 1H, NH);
5.40 (1H, H1′); 4.82 (s, 1H, OH2′); 4.20 (1H, H2′); 4.13 (1H, H3′);
3.93 (1H, OH3′); 3.87 (2H, CH5′); 3.81 (1H, OH5′); 3.73 (1H, H4′).
2.3.6. cis-[(PPh3)2PtHN=C(Ph){Cyt(−2H)}]NO3 (5b)
cis-[(PPh3)2Pt(μ-OH)]2(NO3)2, (30.9 mg, 0.0193 mmol) and cytidine
(9.8 mg, 0.0387 mmol) were suspended in 5 mL of PhCN and heated at
50 °C for ½h. After stirring at r.t. for 24 h, some traces of solid were
removed by filtration. Addition of Et2O to the resulting yellow solution,
afforded a yellow solid which was recovered by filtration, washed with
Et2O and dried under vacuum. 25 mg of compound 5b were obtained
(yield 57%). El. An. Calc. for C52H47N5O8P2Pt: C: 55.42; H: 4.21; N: 6.21.
Found: C: 55.82; H: 4.44; N: 6.45. 31P{1H} NMR in PhCN (D2O insert): AB
multiplet at δ (ppm)=7.90 (1JPPt=3436 Hz) and 7.65 (1JPPt=3436 Hz)
with 2JPP=25.1 Hz), 1H NMR in CDCl3 (δ, ppm): 7.98(d, 1H, H6, 3JHH=
7.20 Hz); 7.68–7.07 (c.m. 30 H, PPh3); 6.24 (d, 1H, H5, 3JHH=7.20 Hz);
6.00 (br dd (broad doublet of doublet), 1H, NH, 3JHP=5.3 Hz); 5.40 (1H,
H1′); 4.87 (s, 1H, OH2′); 4.30 (1H, H2′); 4.06 (1H, H3′); 3.93 (3 H, H5′
and OH3′); 3.77 (1H, H4′); 3.67 (s,1H, OH5′).
2.3.7. cis-[(PPh3)2PtHN=C(Me){Ado(−2H)}]NO3 (6a)
This complex has been synthesized in the same way of 5a starting
from cis-[(PPh3)2Pt(μ-OH)]2(NO3)2, (50.4 mg, 0.032 mmol) and aden-
osine (16 mg, 0.06 mmol). The reactionmixture was stirred for 5 days
at r.t., obtaining 48 mg (yield 73%) of product.
El. An. Calc. for C48H45N7O7P2Pt: C: 52.94; H: 4.17; N: 9.00. Found:
C: 52.62; H: 4.28; N: 8.85. 31P{1H} NMR and CH3CN (D2O insert): AB
multiplet at δ (ppm)=12.11 (1JPPt=3254 Hz) and 10.46 (1JPPt=
3419 Hz) with 2JPP=24.9 Hz.
1H NMR in CDCl3 (δ, ppm): 8.02 (s, 1H, H2); 7.63–7.20(c.m. 31H,
PPh3 and H8); 6.35 (br s, 1H, NH); 5.72 (br dd, 1H, H1′) 5.68 (br s, 1H,
H2′); 4.95 (1H, OH2′); 4.25 (3 H, H3′; H4′ and OH3′); 4.16 (1H, OH5′);
3.66 (2H, H5′).
2.3.8. cis-[(PPh3)2PtHN=C(Ph){Ado(−2H)}]NO3 (6b)
This complex has been synthesized in the same way of 6a starting
from cis-[(PPh3)2Pt(μ-OH)]2(NO3)2, (32.8 mg, 0.02 mmol) and aden-osine (11 mg, 0.04 mmol). 29 mg of compound 6b were obtained
(yield 61%). El. An. Calc. for C53H47N7O7P2Pt: C: 55.30; H: 4.12; N:
8.51. Found: C: 55.70; H: 4.32; N: 8.75. 31P{1H} NMR in PhCN (D2O
insert): AB multiplet at δ (ppm)=11.00 (1JPPt=3281 Hz) and 9.35
(1JPPt=3393 Hz) with 2JPP=24.6 Hz 1H NMR in CDCl3 (δ, ppm): 8.06
(s, 1H, H2); 7.65–7.14(c.m. 31H, PPh3 and H(8)); 6.24 (br s, 1H, NH);
5.73 (br dd 2H, H1′ and H2′); 4.99 (1H, OH2′); 4.38 (3 H, H3′; H4′ and
OH3′); 4.18 (1H, OH5′); 3.65 (2H, H5′).2.4. Experiments with human cell lines
Pt(II) nucleosides (1–4) as well as the corresponding Pt(II)
amidine nucleoside (5b, 6b) and nucleobase (7a, 7b, 8a, and 8b)
derivatives were dissolved in DMSO just before the experiment and a
calculated amount of drug solution was added to the growth medium.
The final solvent concentration was 0.5%, which had no discernible
effect on cell killing. Cisplatin was dissolved in purified water just
before the experiment. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) and cisplatin were obtained from Sigma
Chemical Co, St.Louis, USA.2.4.1. Cell cultures
Human breast (MCF-7) carcinoma cell line along with melanoma
(A375) cell line were obtained by American Type Culture Collection
(ATCC, Rockville, MD). 2008 and its cisplatin resistant variant, C13*, are
human ovarian cancer cell lines, and they were kindly provided by Prof.
G. Marverti (Dept. of Biomedical Science of Modena University, Italy).
A431 and A431/Pt are sensitive and resistant human cervical carcinoma
cells, respectively; kindly provided by Prof. F. Zunino (Division of
Experimental Oncology B, Istituto Nazionale dei Tumori, Milan, Italy).
LoVo human colon-carcinoma cell line and its derivative multidrug-
resistant sub-line (LoVo MDR) were kindly provided by Prof. F. Majone
(Dept. of Biology of PadovaUniversity, Italy). Cell linesweremaintained
in the logarithmic phase at 37 °C in a 5% carbon dioxide atmosphere
using the following culture media containing 10% fetal calf serum
(Euroclone, Milan, Italy), antibiotics (50 units·mL−1 penicillin and
50 μg·mL−1 streptomycin) and 2 mM L-glutamine: i) RPMI-1640
medium (Euroclone) for MCF-7, 2008, C13* cells; ii) F-12 HAM'S
(Sigma Chemical Co) for A431, A431/Pt cells LoVo and LoVo MDR
(LoVo MDR culture medium also contained 0.1 μg·mL−1 doxorubicin);
iii) d-MEM “Dulbecco's modified eagle'smedium” (Euroclone) for A375
cells.2.4.2. Cytotoxicity assays
MTT test. The growth inhibitory effect towards tumor cell lines
was evaluated by means of MTT (tetrazolium salt reduction) assay
[24,25]. Briefly, 3–8·103 cells/well, dependent upon the growth
characteristics of the cell line, were seeded in 96-well microplates
in growth medium (100 μL) and then incubated at 37 °C in a 5%
carbon dioxide atmosphere. After 24 h, the medium was removed
and replaced with a fresh one containing the compound to be
studied at the appropriate concentration. Triplicate cultures were
established for each treatment. After 72 h, each well was treated
with 10 μL of a 5 mg·mL−1 MTT saline solution, and following 5 h of
incubation, 100 μL of an SDS solution in HCl 0.01 M was added.
After overnight incubation, the inhibition of cell growth induced by
the tested complexes was detected by measuring the absorbance of
each well at 570 nm using a Bio-Rad 680 microplate reader. Mean
absorbance for each drug dose was expressed as a percentage of the
control untreated well absorbance and plotted vs. drug concentra-
tion. IC50 values represent the drug concentrations that reduced the
mean absorbance at 570 nm to 50% of those in the untreated control
wells.
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3.1. Syntheses of the nucleoside complexes
As previously shown for the model nucleobase 1-MeCy [18],
cytidine reacts with the dinuclear hydroxo complex cis-[(PMe3)2Pt
(μ-OH)]2(NO3)2, to give the trinuclear species cis-[(PMe3)2Pt{μ-cyt
(−H),N3N4}]3(NO3)3, 1, inwhich the N(4)-deprotonated nucleoside
binds two metal centers through the N3,N4 atoms (Scheme 2).
The condensation reaction, carried out in DMF solution was moni-
tored by 31P NMR spectroscopy showing that, at room temperature, a
complexmixture of products is formed. At 70 °C, in a fewdays, it converts
quantitatively into the trinuclear species 1 characterized by two AB
multiplets, having relative intensities of 2:1, at δ −27.01 (1JPPt=
3126 Hz), 28.31 (3234 Hz) at δ −27.14 (1JPPt=3126 Hz), 28.58
(3234 Hz, with 2JPP=24.8 Hz) ppm, respectively. The 31P NMR param-
eters of the isolated complex, in DMSO-d6, collected in Table 1, are very
similar to those of the nucleobase analogous, structurally characterized
[18]. The presence of two sets of signals for the nucleoside is in line with
the existence of two conformers resulting in the relative orientation, syn
and anti, of the ribose groups with respect to the pyrimidinic ring.Table 1
31P and selected 1H NMR data in DMSO-d6 for the complexes 1–4 and the analogous comp
Compound PA (1JPPt)
cis-[(PMe3)2Pt{cyd(−H),N3N4}]3(NO3)3 1 −27.06 (3266)
−27.26 (3266)
cis-[(PMe3)2Pt{1-MeCy(−H),N3N4}]3(NO3)3 [18] −27.77 (3221)
cis-[(PPh3)2Pt{cyd(−H),N4}(cyd,N3)]NO3 2 12.14 (3190)
12.11 (3190)
cis-[(PPh3)2Pt{1-MeCy(−H),N4}(1-MeCy,N3)]NO3 [19] 12.34 (3241)
cis-[(PMe3)2Pt{ado(−H),N1N6}]2(NO3)2 3 −29.81 (3025)
−29.83 (3025)
cis-[(PMe3)2Pt{9-MeAd(−H),N1N6}]2(NO3)2 [23] −30.33 (3004)
cis-[(PPh3)2Pt{ado(−H),N6N7}]NO3 4 8.74 (3874)
cis-[(PPh3)2Pt{9-MeAd(−H),N6N7}]NO3 [26] 9.20 (3850)The nature of the phosphine ligands plays an important role on the
nuclearity of the nucleoside adducts. In fact, reaction of cytidine with
cis-[(PPh3)2Pt(μ-OH)]2(NO3)2 gives only the mononuclear bis-adduct
cis-[(PPh3)2Pt{cyt(−H),N4}(cyt,N3)]NO3, 2, containing two molecules
of nucleoside, one neutral N3-coordinated, and one N4-deprotonated,
coordinated at the same metal center (Scheme 2).
Similarly, adenosine reacts with cis-[(PPh3)2Pt(μ-OH)]2(NO3)2
giving the mononuclear species cis-[(PPh3)2Pt{ado(−H),N6N7}]NO3,
4, in which the N(6)-deprotonated nucleoside binds the metal center
through the N6,N7 atoms (Scheme 2). On the contrary, cis-[(PMe3)2Pt
(μ-OH)]2(NO3)2, forms the cyclic dinuclear species cis-[(PMe3)2Pt{μ-
ado(−H),N1N6}]2(NO3)2, 3, in which the adenosinate ions act as
bridging ligands, binding two metal centers through the N1 and N6
atoms.
The reaction of the hydroxo complexwith the bulkier PPh3 ligands,
was carried out in DMF or CH2Cl2/MeOH solution and monitored by
31P NMR spectroscopy. In both cases, complex 4 was formed in high
yield (N80%). The 1H and 31P analysis of the isolated solid indicates the
formation of a single species whose proton resonances were
attributed analyzing the COSY (1H–1H COrrelation NMR Spectrosco-
pY) spectrum (reported in Fig. S1 of the Supplementary Material)lexes with the corresponding nucleobases. δ in ppm and J in Hz.
PB (1JPPt) 2JPP H2/H5 H8/H6 NH6/NH4
−28.59 (3097) 20.4 5.97 7.49 7.27
−28.33 (3097) 20.6
−29.14 (3135) 24.4 6.05 7.44 6.46
0.36 (3615) 20.4 5.30 7.22 8.58
0.41 (3615) 20.6 5.09 7.49 8.55
5.50
0.21 (3452) 20.0 5.25 6.66 10.63
4.98 8.34
5.07
−30.48 (3233) 26.4 8.36 8.16 6.81
−38.38 (3233) 26.6 8.35 8.14 6.78
−30.98 (3236) 26.1 8.11 8.02 6.58
5.64 (3131) 19.9 8.05 6.76 5.20
5.57 (3162) 20.0 8.03 6.62 4.51
Fig. 2. 31P-1H HMBC NMR experiment in CDCl3 of the complex 4.
923D. Montagner et al. / Journal of Inorganic Biochemistry 105 (2011) 919–926whereas the binding mode of the nucleoside was established by
15N–1H and 31P–1H HMBC experiments in CDCl3 (Figs. 1 and 2).
Theproton resonances at δ5.43 and5.83 ppm, attributable to theH1′
and H8 adenosine protons, respectively, correlate with the 15N nucleus
at δ−200.0 ppm, assigned toN(9). TheH8proton further correlates also
with N(7) at δ −191.4 ppm. The proton resonance at δ 8.13 ppm,
assigned toH2, correlateswith the 15N resonances at δ−160.9 (N1) and
at−135.2 ppm N(3). Finally, theN(6)Hproton at δ 4.64 ppm (Figure S2
Supplementary Material) correlates with N(6) at δ −242.1 ppm and
exhibits the expected couplings 1JNH=84 and 2JNP=88 Hz.
The 31P NMR spectrum exhibits an AB multiplet, with sharp 195Pt
satellites, at δ 8.26 (1JPPt=3846 Hz) and 6.58 (1JPPt=3124 Hz). As
shown in Fig. 2, the first resonance correlates with the adenine H8
proton at δ 5.83 and both of them show correlation with the N(6)H
proton at δ 4.64 (partially overlappedwith the ribose H2′multiplet, at
300 MHz). These results led to the conclusion that the nucleoside is
chelated to the metal through the N6 and N7 atoms, as previously
found for the nucleobase 9-methyadenine [26]. Selected 31P and 1H
NMR data of the nucleosides and the correspondingmodel nucleobase
are collected in Table 1. It is noteworthy that the replacement of the
methyl group with the ribose does not change significantly the
spectroscopic parameters of these nucleobase/nucleoside adducts.
As anticipated, adenosine reacts with cis-[(PMe3)2Pt(μ-OH)]2
(NO3)2, to give the dinuclear species cis-[(PMe3)2Pt{μ-ado(−H),
N1N6}]2(NO3)2, 3, that has been isolated as a pure compound per-
forming the condensation reaction in water (see Section 2). The
coordination mode of the nucleoside was established by comparison
of the multinuclear NMR data with those of the nucleobase analog cis-
[(PMe3)2Pt{μ-9-MeAd(−H),N1N6}]2(NO3)2 [23], (Table 1) and cis-
[(PMe3)2Pt{μ-9-EtAd(−H),N1N6}]2(NO3)2 [27]. For this last adduct
the N1,N6-coordination of the nucleobase was confirmed by X-ray
analysis [27]. The dinuclear species for 3 is characterized by the
presence of two AB multiplets in the 31P NMR spectrum, as well as of
distinct resonances for the nucleobase H2, H8 and N(6)H protons (see
Table 1), in line with the existence of two conformers resulting in the
relative orientation, syn and anti, of the ribose groups with respect to
the coordination plane of the metal.
The reaction, monitored via 31P NMR spectroscopy, in DMSO, leads
initially to a mixture of products that slowly rearranges quantitatively
into the thermodynamically stable species 3. As an example, the 31P
NMR spectrum of the mixture containing cis-[(PMe3)2Pt(μ-OH)]2
(NO3)2 and ado (molar ratio 1:2) in DMSO-d6 is shown in Fig. 3.
The spectrum obtained immediately after the dissolution of the
reagents shows still a small amount of the reacting hydroxo complexFig. 1. 15N-1H HMBC NMR experiment (long range, evolution time 55 ms) in CDCl3 of
the complex 4.(singlet at δ −23.9 ppm), in agreement with a relatively slow conden-
sation reaction at ambient conditions. The main product (Fig. 3a) is
characterized by an AB multiplet at δ −26.64 (1JPPt=3285 Hz) and
−28.13 (1JPPt=3111 Hz; 2JPP=25.2 Hz), tentatively attributed to
mononuclear N6,N7-chelate analogous to 4 or its linkage isomer cis-
[(PMe3)2Pt{ado(−H),N1N6}](NO3). In a few days at 27 °C, these signals
are completely replaced by two ABmultiplets, having relative intensities
ca. 45:55, at higher field (Fig. 3b), attributable to the isolated dinuclear
species 3. The spectrumdoes not change after 4 days at 75 °C, suggesting
a high stability of the dimeric structure of this adduct.
3.2. Syntheses of the amidine complexes
When the reaction of cis-[(PPh3)2Pt(μ-OH)]2(NO3)2 with the nucle-
osides cyt and ado is carried out in solution of nitriles (RCN, R=Me, Ph)
the amidine derivatives cis-[(PPh3)2PtNH=C(R){cyt(−2H)}]NO3
(R=Me, 5a; R=Ph, 5b) and cis-[(PPh3)2PtNH=C(R){ado(−2H)}]NO3
(R=Me, 6a: R=Ph, 6b), depicted in Scheme 3, are formed.
The formal insertion of a nitrile molecule into a Pt-nitrogen bond
of the cytidine that occurs at room temperature in a few hours, isFig. 3. {1H}31P NMR experiments of the mixture between cis-[(PMe3)2Pt(μ-OH)]2
(NO3)2 and adenosine (1:2) in DMSO-d6. a) immediately after the dissolution; b) after
4 days at 27 °C.
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Scheme 3. Pathway reaction for amidine complexes 5a,b and 6a,b.
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the contrary, in the case of adenosine the initial product is the
nucleoside adduct 4, which slowly reacts with the solvent to give the
amidines 6a,b.
The products have been isolated, in good yield, as pale yellow
solids and characterized by elemental analysis and NMR spectroscopy
in CDCl3. The 1H and 31P NMR data are very similar to those exhibited
by the nucleobase analogs [20,21], cis-[(PPh3)2PtNH=C(R){1-MeCy
(−2H)}]NO3 (R=Me, 7a: R=Ph, 7b), cis-[(PPh3)2PtNH=C(R){9-
MeAd(−2H)}]NO3 (R=Me, 8a: R=Ph, 8b) previously characterized.
In Table 2 selected 31P and 1H NMR of these complexes are collected.
Unlike complexes 1–3, the amidine derivatives 6 and 7 show a single
set of resonances in the 31P and 1H spectra, suggesting a preferred
orientation of the ribose group with respect to the nucleobase ring
(single conformation) or a fast rotation around the glycosidic bond.
In solution, complexes 5a and 6a are indefinitely stable only in
CH3CN. In chlorinated solvents (or DMSO) 5a slowly releases CH3CN
and forms reversibly a complex mixture of uncharacterized products
while 6a forms 4.
The analogous complexes with benzonitrile are stable in PhCN as
well as in solution of DMSO or chlorinated solvents.
3.3. Cytotoxicity tests
Pt(II) nucleosides (1–4) as well as the corresponding Pt(II) benza-
midine nucleosides (5b, 6b) and acetamidine (7a, 8a) or benzami-Table 2
31P and selected 1H NMR data in CDCl3 for the complexes 5–6a,b and the analogous comple
Complex PA (1JPPt) P
cis-[(PPh3)2PtHN=C(Me){cyt(−2H)}]NO3 5a 8.47 (3468)
cis-[(PPh3)2PtHN=C(Ph){cyt(−2H)}]NO3 5b 8.50 (3485)
cis-[(PPh3)2PtHN=C(Me){ado(−2H)}]NO3 6a 11.10 (3220) 1
cis-[(PPh3)2PtHN=C(Ph){ado(−2H)}]NO3 6b 11.30 (3256) 1
cis-[(PPh3)2PtHN=C(Me){1-MeCy(−2H)}]NO3 7a 8.99 (3477)
cis-[(PPh3)2PtHN=C(Ph){1-MeCy(−2H)}]NO3 7b 9.03 (3486)
cis-[(PPh3)2PtHN=C(Me){9-MeAd(−2H)}]NO3 8a 11.33 (3385) 1
cis-[(PPh3)2PtHN=C(Ph){9-MeAd(−2H)}]NO3 8b 10.95 (3263) 1
a Overlapped with the PPh3 signals.damide (7b, 8b) nucleobase derivatives were evaluated for their
cytotoxic activity towards a panel of 8 human tumor cell lines inclu-
ding examples of ovarian (2008 and C13*), cervical (A431 and
A4317Pt), colon (LoVo and LoVoMDR) and breast (MCF-7) cancer and
melanoma (A375). Acetamidine Pt(II) nucleosides (5a, 6a) were not
tested for their cytotoxicity owing to their poor stability in DMSO.
Cytotoxicity was evaluated by means of MTT tests after 72 h of
treatment with increasing concentrations of the tested compounds.
For comparison purposes, the cytotoxicity of cisplatin, the most
widely used anticancer metallodrug, was evaluated in the same
experimental conditions. IC50 values, calculated from dose–survival
curves, are shown in Table 3.
Pt(II) nucleosides (1–4) proved to be completely ineffective over
8 cell lines; the negligible activity shown by 1–4 could be associated
with the high kinetic inertness of these molecules as assessed bymass
and NMR studies. Among Pt(II) amidine nucleoside and nucleobase
complexes, cytosine derivatives proved to be much more effective
than those containing adenine. In particular, adenosine and adenine
derivatives 6b, 8a and 8b showed mean IC50 (μM) values of 24.87
(34.24–12.41), 21.68 (24.91–16.34) and 20.55 (24.73–10.47), respec-
tively, which were about four times higher than that of cisplatin
(5.45 μM). Among Pt(II) cytidine and cytosine complexes, acetami-
dine nucleobase 7a showed the worst cytotoxic potency, eliciting a
cancer cell growth inhibition roughly 2.5 times lower than cisplatin.
Conversely, Pt(II) benzamidine nucleobase 7b distinguished itself as
the most promising derivative, being able to decrease cell viabilityxes with the corresponding nucleobases previously characterized. δ in ppm and J in Hz.
B (1JPPt) 2JPP H2/H5 H8/H6 NH
7.92 (3432) 25.0 6.00 7.95 5.50
7.86 (3450) 24.8 6.24 7.98 6.00
0.71 (3417) 23.8 8.02 a 6.35
0.14 (3399) 24.3 8.06 a 6.24
7.77 (3419) 24.8 6.02 7.20 5.72
7.77 (3417) 24.9 6.22 7.14 6.05
0.86 (3369) 24.7 8.11 7.81 5.44
0.70 (3370) 24.5 8.28 7.95 6.32
Table 3
Cytotoxicity.
Compound IC50 (μM)±S.D.
A375 MCF-7 A431 A431/Pt R.F. 2008 C13 R.F. LoVo LoVo MDR R.F.
cis-[(PMe3)2Pt{cyt(−H),
N3N4}]3(NO3)3 1
N100 N100 N100 N100 – N100 N100 – N100 N100 –
cis-[(PMe3)2Pt{ado(−H),
N1N6}]2(NO3)2 3
N100 N100 N100 N100 – N100 N100 – N100 N100 –
cis-[(PPh3)2Pt{ado(−H),
N6N7}]NO3) 4
N100 N100 N100 N100 – N100 N100 – N100 N100 –
cis-[(PPh3)2PtNH=C(Ph)
{cyt(−2H)}]NO3 5b
2.44±1.13 7.55±1.94 3.98±0.69 3.13±2.03 1.0 4.77±1.43 10.32±1.04 0.8 7.34±1.15 8.56±1.47 1.1
cis-[(PPh3)2PtNH=C(Ph)
{ado(−2H)}]NO3 6b
29.83±1.53 31.58±1.41 23.12±1.35 18.48±1.21 0.8 12.41±1.45 20.37±1.85 1.8 28.92±1.25 34.24±2.14 1.4
cis-[(PPh3)2PtNH=C(Me)
{1-MeCy(−2H)}]NO3 7a
6.93±1.31 24.14±2.25 13.52±1.54 11.66±1.12 0.8 7.70±1.16 12.64±1.90 0.8 8.54±2.11 13.24±2.24 1.3
cis-[(PPh3)2PtNH=C(Ph)
{1-MeCy(−2H)}]NO3 7b
2.27±1.00 4.58±1.13 2.87±0.79 2.48±1.01 0.8 3.47±1.02 3.36±1.12 0.9 2.89±1.25 3.85±1.36 1.3
cis-[(PPh3)2PtNH=C(Me)
{9-MeAd(−2H)}]NO3 8a
16.34±1.00 24.67±1.90 22.11±0.94 24.91±1.43 1.1 20.23±3.01 24.41±1.98 1.2 19.54±1.38 21.25±2.55 1.3
cis-[(PPh3)2PtNH=C(Ph)
{9-MeAd(−2H)}]NO3 8b
19.11±1.75 31.15±2.62 23.47±1.28 18.49±1.77 0.7 23.89±1.63 24.73±2.17 1.1 10.47±1.28 13.13±1.96 1.3
Cisplatin 2.47±1.23 9.01±1.54 1.89±1.67 5.81±1.33 3.1 3.75±1.86 32.13±1.76 8.6 7.89±3.02 7.31±2.21 1.0
Antitumor activity via MTT test. IC50 values have been evaluated by probit analysis (pb0.05, test of χ2). Cells have been treated for 72 h with increasing concentration of tested
compounds. Resistant factor (RF) is defined as IC50 resistant/parent line. S.D.: standard deviation.
925D. Montagner et al. / Journal of Inorganic Biochemistry 105 (2011) 919–926about 2 times more effectively than cisplatin (average IC50 of 3.22 μM
and 5.45 μM for 7b and cisplatin, respectively). Pt(II) benzamidine
nucleoside 5b, despite retaining an antiproliferative activity slightly
lower than that of the relative Pt(II) nucleobase complexes 7a and 7b
(average IC50 of 3.22 and 6.01 μM for 7b and 7a, respectively), has
been found to possess a cytotoxic potency quite similar to that of the
reference metallodrug. Among nucleobase amidine Pt(II) complexes,
benzamidine derivatives proved to be more effective with respect
to acetamidine analogs. This behavior may be related to the more
lipophilic properties of the phenyl ring that could favor the crossing of
the cell membrane. These data are in line with the results previously
reported concerning trans-Pt(II) amidine complexes [28,29].
The in-house panel also included two cell lines that have been
selected for their resistance to cisplatin (human ovarian adenocarci-
noma C13* cells, human cervical carcinoma A431/Pt cells). Although
cisplatin resistance is multifactorial, the main molecular mechanisms
involved in Pt resistance of C13* and A431/Pt have been identified. In
particular, in C13* cells' resistance is correlated to reduced cellular
drug uptake, high cellular glutathione and thioredoxin reductase
levels and enhanced repair of DNA damage [30,31]. In A431/Pt cells,
resistance is due to a defect in drug uptake and to decreased levels of
proteins involved in DNA mismatch repair (MSH2), which causes an
increased tolerance to cisplatin-induced DNA damage [32]. By
comparing the RF values (where RF is the resistance factor and is
defined as the ratio between IC50 values calculated for the resistant
cells and those arising from the sensitive ones), new Pt(II) amidine
nucleoside and nucleobase complexes were found to be able to
overcome cisplatin resistance. The resistance factors calculated for
these derivatives were about 8 and 3 times lower than that of cisplatin
on the 2008-C13* and A431-A431/Pt cell pairs, respectively.
Additionally, Pt(II) amidine complexes were tested against a
multidrug resistant (MDR) colon carcinoma subline, LoVo MDR cells.
It is well known that acquired MDR, whereby cells become refractory
to multiple drugs, poses a most important challenge to the success of
anticancer chemotherapy. The resistance of LoVo MDR cells to
doxorubicin, a drug belonging to the MDR spectrum, is associated
with an overexpression of the multi-specific drug transporters, such
as, for example, the 170 kDa P-glycoprotein (P-gp) [33]. Although
cisplatin is not a P-glycoprotein substrate; many multidrug resistance
protein (MRP1, MRP2, MRP4) have been found involved in platinum
complex transport and are responsible for its efflux/afflux from the
cell [34–36]. Cytotoxicity assays testing Pt(II) amidine derivativesagainst this cell line pair showed a similar pattern of response across
the parental and the resistant subline thus suggesting that these new
Pt(II) complexes are not potential MDR substrates.
4. Conclusions
Themain results of this study can be summarized as follows: a) the
substitution of themethyl group in the model nucleobase 1-MeCy and
9-MeAd with the ribose group does not change significantly the
reactivity pattern of these biomolecules toward the hydroxo complex
cis-[L2Pt(μ-OH)]22+. The less hindered phosphines stabilize polynu-
clear adducts in which the deprotonated nucleoside acts as bridging
ligand. The di- and/or trimerization of the nucleoside adducts is
prevented when the hydroxo reagent is stabilized by PPh3. b) A
similar effect of the phosphine ligands is observed in the activation
of nitriles: the insertion of a molecule of CH3CN or PhCN occurs only
with the less basic PPh3. c) Among the isolated complexes, only the
amidine derivatives exhibit a clear cytotoxic activity toward different
human tumor cell lines. In particular, the benzamidine cis-[(PPh3)2-
PtHN=C(Ph){1-MeCy(−2H)}]NO3 (7b) shows interesting properties,
in terms of antiproliferative effects, even toward C13* cisplatin
resistant cells and this important finding could be due to a different
mechanism of action with respect to the reference metallodrug.
Acknowledgements
This work was financially supported by University of Padua and by
Ministero dell'Istruzione dell'Università e della Ricerca. We are
grateful to CIRCMSB (Consorzio Interuniversitario di Ricerca in
Chimica dei Metalli nei Sistemi Biologici).
Appendix A. Supplementary data
Supplementary data to this article can be found online at
doi:10.1016/j.jinorgbio.2011.03.009.
References
[1] B. Lippert, Coord. Chem. Rev. 200–202 (2000) 487–516.
[2] E. Zangrando, F. Pichierri, L. Randaccio, B. Lippert, Coord. Chem. Rev. 156 (1996)
275–332.
[3] B. Lippert, Prog. Inorg. Chem. 54 (2005) 385–447.
[4] B. Rosemberg, L. Van Camp, J.E. Trosko, V.H. Mansour, Nature 222 (1969) 385–386.
926 D. Montagner et al. / Journal of Inorganic Biochemistry 105 (2011) 919–926[5] B. Rosemberg, L. Van Camp, T. Krigas, Nature 205 (1965) 698–699.
[6] B. Rosemberg, in: B. Lippert (Ed.), Cisplatin: Chemistry and Biochemistry of a
Leading anticancer Drug, Wiley-VHC, Zurich, 1999, pp. 3–27.
[7] D.S. Alberts, in: H.M. Pinedo, J.H. Schornagel (Eds.), Platinum and other Metal
Coordination Compounds in Cancer Chemotherapy 2, Plenum Press, New York
and London, 1996, pp. 303–310.
[8] T. Ishibashi, Y. Yano, T. Oguma, Cancer Chemother. Pharmacol. 50 (2002) 230–236.
[9] E. Raymond, S.G. Chaney, A. Taama, E. Cvitkovic, Ann. Oncol. 9 (1998) 1053–1071.
[10] M.D. Hall, T.W. Hambley, Coord. Chem. Rev. 232 (2002) 49–67.
[11] M.S. Ali, S.R.A. Khan, H. Ojima, I.Y. Guzman, K.H. Whitmire, Z.H. Siddik, A.R.
Khokhar, J. Inorg. Biochem. 99 (2005) 795–804.
[12] W.Z. Shen, B. Lippert, J. Inorg. Biochem. 102 (2008) 1134–1140.
[13] Y. Suzuky, M. Tanokura, T. Shimizu, Eur. J. Biochem. 257 (1998) 466–471.
[14] K. Yamanari, R. Yto, S. Yamamoto, T. Konno, A. Fuyuhiro, M. Kobayashi, R.
Arakawa, Dalton Trans. (2003) 380–386.
[15] A. Messere, E. Fabbri, M. Borgatti, R. Gambari, B. Di Blasio, C. Pedone, A. Romanelli,
J. Inorg. Biochem. 101 (2007) 254–260.
[16] J. Arpalahti, K.D. Klika, R. Sillanpää, R. Kivekäs, J. Chem. Soc. Dalton Trans. (1998)
1397–1402.
[17] M. Mikola, K.D. Klika, R. Sillanpää, J. Arpalahti, Chem. Eur. J. 6 (2000) 3404–3413.
[18] L. Schenetti, G. Bandoli, A. Dolmella, G. Trovò, B. Longato, Inorg. Chem. 33 (1994)
3169–3176.
[19] B. Longato, D. Montagner, E. Zangrando, Inorg. Chem. 45 (2006) 8179–8187.
[20] B. Longato, D. Montagner, G. Bandoli, E. Zangrando, Inorg. Chem. 45 (2006)
1805–1814.
[21] D. Montagner, A. Venzo, E. Zangrando, B. Longato, Inorg. Chem. 49 (2010)
2103–2110.[22] G. Trovò, G. Bandoli, U. Casellato, B. Corain, M. Nicolini, B. Longato, Inorg. Chem. 29
(1990) 4616–4621.
[23] L. Schenetti, A. Mucci, B. Longato, J. Chem. Soc. Dalton Trans. (1996) 299–303.
[24] D.T. Vistica, P. Skehan, D.A. Scudiero, A. Monks, A. Pittman, M.R. Boyd, Cancer Res.
51 (1991) 2515–2520.
[25] M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J.
Abbott, J.G. Mayo, R.H. Shoemaker, M.R. Boyd, Cancer Res. 48 (1988) 589–601.
[26] D. Montagner, B. Longato, Inorg. Chim. Acta 361 (2008) 1676–1680.
[27] G. Trovò, G. Bandoli, M. Nicolini, B. Longato, Inorg. Chim. Acta 211 (1993) 95–99.
[28] F.P. Intini, R.Z. Pellicani, A. Boccarelli, R. Sasanelli, M. Coluccia, G. Natile, Eur. J.
Inorg. Chem. (2008) 4555–4561.
[29] S. Mazzega Sbovata, F. Bettio, C. Marzano, M. Mozzon, R. Bertani, F. Benetollo, R.A.
Michelin, Inorg. Chim. Acta 361 (2008) 3109–3116.
[30] D.P. Gately, S.B. Howell, Br. J. Cancer 67 (1993) 1171–1176.
[31] C. Marzano, V. Gandin, A. Folda, G. Scutari, A. Bindoli, M.P. Rigobello, Free Rad. Bio.
Med. 42 (2007) 872–881.
[32] C. Lanzi, P. Perego, R. Supino, S. Romanelli, T. Pensa, N. Carenini, I. Viano, D.
Colangelo, R. Leone, P. Apostoli, G. Cassinelli, R.A. Gambetta, F. Zunino, Biochem.
Pharmacol. 55 (1998) 1247–1254.
[33] C. Wersinger, G. Rebel, I.H. Lelong-Rebel, Amino Acids 19 (2000) 667–685.
[34] Y. Zhou, X.L. Ling, S.W. Li, X.Q. Li, B. Yan, World J. Gastroenterol. 16 (2010)
2291–2297.
[35] S. Kamazawa, J. Kigawa, Y. Kanamori, H. Itamochi, S. Sato, T. Iba, N. Terakawa,
Gynecol. Oncol. 86 (2002) 171–176.
[36] Y.H. Zhang, Q. Wu, X.Y. Xiao, D.W. Li, X.P. Wang, Cancer Lett. 291 (2010) 76–82.
